Market Overview

Jefferies Reiterates Buy Rating, $36 PT on Incyte Corporation Despite PML Case

Share:
Related INCY
Immunovaccine Collaborates With Incyte to Evaluate Novel Immunotherapy Combination for Patients With Platinum-Sensitive Ovarian Cancer
JMP Sees A 'Negative Market Tone' In Biotechnology

In a report published Monday, Jefferies analyst Thomas Wei reiterated a Buy rating and $36.00 price target on Incyte Corporation (NASDAQ: INCY).

In the report, Wei noted, “INCY today disclosed a 75-year old male patient developed PML, a rare brain infection, while taking Jakafi. We still believe that the overall risk-benefit profile of Jakafi is favorable and note that the causal relationship between Jakafi and the PML case is unclear with spontaneous reports of PML in the myelofibrosis literature, and there has been a favorable trend on overall survival seen in the Phase 3 trials.”

Incyte Corporation closed on Friday at $24.84.

Latest Ratings for INCY

DateFirmActionFromTo
May 2015Bank of AmericaInitiates Coverage onBuy
Apr 2015JMP SecuritiesMaintainsMarket Outperform
Feb 2015OppenheimerMaintainsOutperform

View More Analyst Ratings for INCY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Reiteration Analyst Ratings

 

Related Articles (INCY)

Around the Web, We're Loving...

Get Benzinga's Newsletters